Excalibur Management Corp Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Excalibur Management Corp reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the 4th quarter, Holdings Channel reports. The firm owned 23,242 shares of the biopharmaceutical company’s stock after selling 152 shares during the period. Gilead Sciences makes up 0.9% of Excalibur Management Corp’s holdings, making the stock its 29th biggest holding. Excalibur Management Corp’s holdings in Gilead Sciences were worth $2,147,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. State Street Corp boosted its holdings in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares in the last quarter. Wellington Management Group LLP grew its holdings in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. FMR LLC increased its position in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after buying an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Gilead Sciences by 3.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,779 shares of the biopharmaceutical company’s stock worth $739,217,000 after buying an additional 249,804 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.1 %

Shares of NASDAQ:GILD opened at $107.89 on Wednesday. The company has a market capitalization of $134.36 billion, a PE ratio of 291.59, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company’s fifty day moving average is $104.35 and its 200-day moving average is $94.36. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Oppenheimer lifted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.